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Background: Delayed diagnosis and treatment of Acute Myocardial Infarction (AMI) has a major adverse impact on
prognosis in terms of both morbidity and mortality. Since conventional cardiac Troponin assays have a low sensitivity
for diagnosing AMI in the first hours after myocardial necrosis, high-sensitive assays have been developed. The aim of
this study was to assess the cost effectiveness of a high-sensitive Troponin T assay (hsTnT), alone or combined with the
heart-type fatty acid-binding protein (H-FABP) assay in comparison with the conventional cardiac Troponin (cTnT) assay
for the diagnosis of AMI in patients presenting to the hospital with chest pain.
Methods: We performed a cost-utility analysis (quality adjusted life years-QALYs) and a cost effectiveness analysis (life
years gained-LYGs) based on a decision analytic model, using a health care perspective in the Dutch context and a life
time time-horizon. The robustness of model predictions was explored using one-way and probabilistic sensitivity analyses.
Results: For a life time incremental cost of 30.70 Euros, use of hsTnT over conventional cTnT results in gain of 0.006 Life
Years and 0.004 QALY. It should be noted here that hsTnT is a diagnostic intervention which costs only 4.39 Euros/test
more than the cTnT test. The ICER generated with the use of hsTnT based diagnostic strategy comparing with the use of
a cTnT-based strategy, is 4945 Euros per LYG and 7370 Euros per QALY. The hsTnT strategy has the highest probability of
being cost effective at thresholds between 8000 and 20000 Euros per QALY. The combination of hsTnT and h-FABP
strategy’s probability of being cost effective remains lower than hsTnT at all willingness to pay thresholds.
Conclusion: Our analysis suggests that hsTnT assay is a very cost effective diagnostic tool relative to conventional TnT
assay. Combination of hsTnT and H-FABP does not offer any additional economic and health benefit over hsTnT test alone.
Keywords: Cost-effectiveness, Decision model, Acute myocardial infarction, High-sensitive troponin TBackground
Acute coronary syndrome (ACS) is a major cause of mor-
bidity and mortality around the world. The most common
manifestation of ACS is acute myocardial infarction
(AMI). It is widely accepted that early detection and treat-
ment of AMI has a major impact on AMI morbidity and
mortality and therefore on associated costs [1-3]. Accord-
ing to the current guidelines, AMI is diagnosed on the* Correspondence: a.vaidya@maastrichtuniversity.nl
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unless otherwise stated.basis of presenting symptoms (chest pain, shortness of
breath epigastric discomfort etc.), electrocardiographic
(ECG) findings and dedicated blood biomarkers of cardiac
necrosis [4]. However, less than 25% symptomatic patients
are finally diagnosed with AMI [5], while ECG alone may
remain non diagnostic in up to 50% of cases [6]. This
makes cardiac biomarker testing an important additional
measure for the diagnosis of AMI.
In current clinical practice cardiac troponin T (cTnT) is
the preferred biochemical marker for myocardial cell necro-
sis [4]. Since elevated cTnT levels are detected only 8–12
hours after onset of ischemic symptoms, the low sensitivity
of cTnT assay at time of presentation is a major drawback
in its use [7]. The life threatening nature of AMI and theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lead to over-triage of patients and substantial costs to the
health system [2,8].
A recently published study has concluded that high-
sensitive Troponin T (hsTnT) is a useful prognostic
biomarker in patients with symptoms of chest discom-
fort suspected for ACS [9]. Two multi centre studies
have suggested that high-sensitivity Troponin assays
offer superior diagnostic accuracy for the early diagnosis
of AMI compared to the conventional cTnT assay [7,10].
Another AMI biomarker, heart-type fatty acid-binding
protein (H-FABP), was reported to appear in the blood
within one hour of myocardial necrosis and peaks after
3–4 hours [11]. Although H-FABP is not recommended
as stand-alone test for diagnosis of AMI[12], combined
sensitivity of cardiac troponin and H-FABP is reported
to be higher than cardiac Troponin alone [13].
In this study we assessed the cost effectiveness of the
hsTnT assay and combination of hsTnT (fifth generation
TnT assay) and H-FABP assays for the early diagnosis of
AMI in comparison with the currently in clinical practice
conventional fourth generation TnT assay. To the best of
our knowledge, no economic evaluation study has yet
been published in Eurozone on the conventional TnT
assay based diagnostic approach versus new alternatives
involving hsTnT and H-FABP assays.Figure 1 Decision Tree Structure for Diagnosis of AMI. Square node is
strategy. Circles represent chance nodes or probabilities. Triangular termina
decision tree. Patient is discharged alive from the hospital or dies during hMethods
Decision analytic model tree
This study was done in the Dutch context using a health
care perspective. A decision tree was constructed to
compare the costs and outcomes associated with three
diagnostic strategies under evaluation in a hypothetical
cohort (Figure 1).
Diagnostic strategies
1. cTnT assay at <6 hours of symptom onset, which
will be repeated after <12 hours of symptom onset,
in the case of negative test result and continuing
symptoms.
2. hsTnT assay at <6 hours of symptom onset, which
will be repeated after <12 hours of symptom onset,
in the case of negative test result and continuing
symptoms.
3. hsTnT and H-FABP assays at <6 hours of symptom
onset, which will be repeated after <12 hours of
symptom onset, in the case of negative test result
and continuing symptoms.
Correct or incorrect diagnosis of AMI and subsequent
events in the model are followed for patients with chest
pain presenting to the hospital. This diagnostic work updecision node where patient is assigned to one of the competing
l nodes represent the end of the paths from left to right through
ospitalization. Patient survives AMI lives life expectancy of AMI survivor.
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guide the treating physician to employ the therapeutic
intervention i.e. primary percutaneous coronary interven-
tion (PPCI). PPCI is the preferred therapeutic modality to
treat AMI and in The Netherlands majority of patients are
treated with PPCI [14,15].
The whole process will culminate into either death or
survival of the patient during hospital admission. Patient
endpoint can be either alive at the end of hospitalization
or dead, after presenting to hospital for suspected cardiac
chest pain. For the theoretical AMI survivor an average
life expectancy was assigned from the literature [16], indi-
cating the time horizon for this modelling study to be life
time. Although the exact moment in time is unknown,Table 1 Model input parameters
Parameter Deterministic va
Costs & event occurrence
Cost of conventional cTnT test €17.11(12.8-21.4)
Cost of new hsTnT test €31.5 (23.6-39.4)
Cost of AMI in 1st year € 12446 ( 9334–15
Cost of AMI in subsequent year € 2092 (1569–261
Utility score for AMI 0.725 (0.544-0.906
Discount rate: cost 0.4
Discount rate: Effect 0.15
Prevalence of AMI among patients presenting
with chest pain
0.30 (0.23 -0.38)
Risk adjusted mortality ratio among inappropriately
discharged AMI patients
1.9 (1.43 -2.38)
Life expectancy of AMI survivor (years) 8.3 (6.23-10.38)
Diagnostic accuracy
cTnT sensitivity at ≤6 hours 0.44 (0.32-0.56)
cTnT sensitivity at ≤12 hours 0.93 (0.85-0.97)
cTnT specificity at ≤6 hours 0.92 (0.88-0.95)
cTnT specificity at ≤12 hours 0.85 (0.76-0.91)
hsTnT sensitivity at ≤6 hours 0.94 (0.87-0.98)
hsTnT sensitivity at ≤12 hours 0.95 (0.91-0.98)
hsTnT specificity at ≤6 hours 0.52 (0.39-0.65)
hsTnT specificity at ≤12 hours 0.51 (0.40-0.62)
hsTnT + hFABP sensitivity at ≤6 hours 0.97 (0.90-0.99)
hsTnT + hFABP sensitivity at ≤12 hours 0.97 (0.93-0.99)
hsTnT + hFABP specificity at≤ 6 hours 0.39 (0.27-0.51)
hsTnT + hFABP specificity at≤ 12 hours 0.38 (0.27-0.49)
Event occurrence
Average of AMI mortality among patients given PPCI
within 4 hours of presentation
0.062 (0.0468-0.07
AMI mortality among patients given PPCI after 4 hours
of presentation
0.103 (0.077-0.128
PPCI procedure related mortality 0.0072 (0.0054-0.0
*Time & Motion study done at Pathology Laboratory, MUMC.patients who died during the period of hospitalization
were assigned a life expectancy of zero. We assumed that
the diagnosis of AMI is excluded in those patients who
remained negative after 2 consecutive testing.
Model input parameters
Beside life expectancy and utility values, other parameters
used in this model are probabilities of events and costs.
Parameters fed into the model are computed from raw
parameters obtained from the existing literature and from
financial affairs department of Maastricht university med-
ical centre (MUMC) (Table 1). The data for test accuracy
of cTnT, hsTnT and hsTnT-H-FABP was determined from
the diagnostic testing on the preserved blood sampleslues (min – max range) Distribution Source
Beta PERT Commercial price at MUMC






















80) Beta PERT Calculated from [3]
8) Beta PERT [3]
09) Beta PERT [18]
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Germany as presented by Bongaerts et al. [17].
Event probability calculation
Application of Bayes’ Theorem allows us to interpret the
test results. Pre-test probability or prior probability of
presence/absence of a disease is calculated using Bayesian
revision. Prevalence of AMI among symptomatic patients
presenting at hospital and diagnostic test sensitivity and
specificity are used to calculate various event probabilities.
Prevalence of AMI among symptomatic patients present-
ing to hospital as reported in a large multi-centre study
[5] is used in our model.
Post PPCI mortality among AMI patients is abstracted
from the literature. Mortality increases with delay in PPCI
and is reported from 15 minutes until 240 minutes delay
in PPCI after presentation [3]. Average mortality, calcu-
lated from mortality reported at different points of time
between 15 minutes to 240 minutes, is used in our model
after initial biomarker testing at presentation. Average
mortality for patients given PPCI within 4 hours of pres-
entation is 6.24%. Mortality among patients in whom
PPCI is delayed by ≥4 hours is assumed to be 10.3% based
on the mortality figure reported in the literature for PPCI
at 240 minutes.
Procedural mortality related to PPCI [18], post AMI
life expectancy [16] utility score for AMI survivors [19]
and mortality among inappropriately discharged AMI
patients in comparison to hospitalized patients [20] are
taken from the published literature.
Cost calculation
The cost of diagnostic cTnT test was 17.11 Euros (data ob-
tained from the financial affairs department of Maastricht
university medical centre (MUMC) database. MUMC pub-
lishes standard prices of health care products available at
the MUMC every year in a freely available database [21].
Cost estimates for the new diagnostic tests hsTnT/hFABP
(i.e. 21.50 euro), were based on the database, consultation
with experts and an in-house time and motion study per-
formed by a senior laboratory technician at the Pathology
department of the MUMC who recorded the various stages
of test procedure in a time sheet. The unit costs of
resources identified for performing the assay was used to
calculate the total cost per diagnostic test. Costs incurred
in the first year of AMI survival are higher as the primary
cost driver is PPCI as a therapeutic intervention. The
Dutch costs for the AMI survivors for first year and subse-
quent years were taken from the published literature [22].
All costs used in the model were converted to Year 2012
costs using harmonized index of consumer prices data
from the Dutch bureau of statistics [23].
Longer term costs and outcomes are discounted as per
the Dutch pharmacoeconomic guidelines [24].Outcome measures
The effectiveness of diagnostic test strategies is mea-
sured in terms of survival probabilities in AMI patients
during hospitalization and incremental life years gained
(LYGs) by AMI survivors. Quality adjusted life years
(QALYs) are derived by multiplying LYGs with the Post
AMI utility score reported in the literature [19].
Analyses
The expected costs and outcomes of all the three strat-
egies were calculated and incremental cost effectiveness
ratios were determined. Cost effectiveness analysis(CEA)
and cost-utility analysis (CUA) are approaches to com-
pare the costs and health outcomes of a new interven-
tion with the existing practice [25]. An incremental cost
effectiveness Ratio (ICER) is calculated by dividing dif-
ferential costs with differential effects between existing
practice and the new health technology. When more
than one, ‘new technologies’ are under evaluation then
the more costly technology is compared with the less
costly technology [26].
The probabilistic sensitivity analysis (PSA) considers
uncertainties in all the model parameters simultaneously.
Probabilistic sensitivity analysis quantifies the uncertainty
in the ICER, by placing a probability distribution over par-
ameter values. Test accuracy parameter values were varied
in the full range of their reported 95% confidence interval
(CI). Other parameter values were varied between 75%
and 125% of their point estimates. The model parameters
were assigned BETA distribution and BETA Pert distribu-
tion was used if confidence intervals or standard errors
were not reported in the source literature. BETA Pert
distribution is a version of the Beta distribution. The costs
of AMI treatment were assigned GAMMA distribution.
Probabilistic sensitivity analysis of the model parameters
with 1,000 iterations using Monte Carlo simulation tech-
nique yields a range of health outcome results. Net mon-
etary benefit (NMB) framework was applied to Monte
Carlo simulation data to construct the cost effectiveness
acceptability curves (CEACs). This framework offers an
advantage of unambiguously sorting out the acceptability
of an individual simulation trial on cost effectiveness
plane, for a range of ‘willingness to pay’ values [25,27].
We performed one way sensitivity analyses to assess the
degree of change in results with variation of one model in-
put parameter value at a time. All parameters were were
varied in the full range of their reported 95% confidence




The expected values for the three strategies namely con-
ventional cTnT, hsTnT and combination of hsTnT and
Table 2 Base-case results costs and effects
Diagnostic strategies Increments
cTnT hsTnT hsTnT + H-FABP hsTnT vs cTnT hsTnT + H-FABP vs cTnT hsTnT + H-FABP vs hsTnT
Discounted cost € 15115.62 € 15137.2 € 15187.74 € 30.70 € 86.61 € 55.91
Discounted LYGs 2.286 2.292 2.296 0.006 0.010 0.0037
Discounted QALYs 1.657 1.662 1.664 0.004 0.007 0.0025
ICER
Incremental cost per LYG Incremental cost per QALY
cTnT Reference strategy Reference strategy
hsTnT vs cTnT € 4945 € 7370
hsTnT + H-FABP vs cTnT € 8780 € 13084
hsTnT + H-FABP vs hsTnT € 15286 € 22781
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Table 2. The constructed model predicts that when a
diagnosis is made using hsTnT instead of conventional
TnT, a hypothetical AMI survivor will live 0.006 years
(Life Year Gain-LYG) longer and will have additional
0.004 QALYs for an incremental cost of 30.70 Euros. It
should be noted here that hsTnT is a diagnostic inter-
vention which costs only 4.39 Euros/test more than the
cTnT test. The ICER generated with the use of hsTnT
based diagnostic strategy comparing with the use of a
cTnT-based strategy, is 4945 Euros per LYG and 7370
Euros per QALY. Combination strategy of the hsTnT
assay with the H-FABP assay is the next more costly
new technology and as per the decision modelling guide-
lines it is compared with less costly hsTnT [26]. Com-
parison of combination arm with hsTnT alone arm
shows 0.0037 and 0.0025 additional LYGs and QALYs
respectively, at an incremental cost of 55.91 Euros lead-
ing to an ICER of 15286 per LYG and 22781 Euros per
QALY. Details of costs, outcomes and increments for all
strategies are presented in the Table 2.Figure 2 Cost effectiveness acceptability curve(s) shows likelihood th
acceptable ceiling ratios society is willing to pay for the gain of one QProbabilistic sensitivity analysis
The probabilistic results of the decision model are similar
to the deterministic results hsTnT as cost effective diag-
nostic strategy. Figure 2 shows the probability in the PSA
that each strategy is cost effective at various thresholds of
willingness to pay ranging from zero to 20000 Euros.
hsTnT strategy has the highest probability of being cost
effective at thresholds between 8000 and 20000 Euros per
QALY. The combination of hsTnT and h-FABP strategy’s
probability of being cost effective remains lower than
hsTnT at all willingness to pay thresholds and was not
analysed further by one way sensitivity analysis.One way sensitivity analysis
The constructed model was robust to all one way sensitivity
analyses and ICER remains less than 12000 Euros per
QALY which is far below the acceptable willingness to pay
per QALY limit of 20000 Euros in The Netherlands. The
results of one way sensitivity analyses are graphically dis-
played as a tornado diagram in the Figure 3. This figureat a strategy would be cost effective for a range of maximum
ALY, assessed with 1000 Monte Carlo simulations.
Figure 3 One way sensitivity analysis: Tornado diagram.
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results (ICER).
Discussion
This modelling study assessed the cost effectiveness of
two biomarker strategies for the early diagnosis of AMI
i.e. hsTnT and the combination of hsTnT and H-FABP.
Economic and clinical consequences of using these new
tests instead of conventional cTnT test were extrapolated
by decision modelling. Our findings suggested that hsTnT
is a cost effective tool to diagnose AMI at the Emergency
Department in patients presenting with chest pain. Use of
hsTnT diagnostic assay resulted in gain of additional
QALYs compared with the existing 4thgeneration diagnos-
tic cTnT test. A combination strategy of performing the
5thgeneration hsTnT and H-FABP assays simultaneously
did not bring any additional benefit and even incurred
higher costs.
This study was performed with a health care payer’s
perspective. The societal perspective for this study was
not considered because the average age of AMI patients
in The Netherlands is 66.7 years [28]. Therefore, prod-
uctivity loss in this age group may not be significant and
impact of this effect was not weighed or included. Indir-
ect costs associated with time spent by family members
for the care of these patients are also difficult to estimate
for the societal perspective.
A potential limitation of this study is that the probabil-
ities of clinical outcomes in our model are derived from
diagnostic accuracy estimates for hsTnT and H-FABP
from a single cohort with relatively small number of
patients from Bad Nauheim Acute Coronary Syndrome
II Registry, Germany. However, in sensitivity analysis ourtest accuracy data was varied between full ranges of confi-
dence interval (CI) limits to test the robustness of the
model. Application of the net monetary benefit (NMB)
framework revealed the dominance of hsTnT strategy
showing highest net monetary benefit for it. Furthermore,
a recently published meta-analysis [29] for diagnostic ac-
curacy of cTnT and hsTnT at the time of patient’s presen-
tation to the emergency department has similar accuracy
figures as our source article by Bongaerts et al. [17].
This study shares the general limitations of economic
modelling. Complex medical practice is difficult to trans-
form into a decision tree model. This applies to our
model as well. All test positive patients will not undergo
PPCI in real life situation. Repeated biomarker testing,
clinical judgment and ECG findings play a crucial role in
decision making on invasive intervention. Our decision
tree model attempts to reflect the true clinical practice
as closely as possible and the model’s robustness has
been rigorously tested for changes in clinical and economic
variables. All the model assumptions and uncertainties
were addressed by performing one way sensitivity analysis
and state-of-the-art Probabilistic Sensitivity Analysis. PSA
is one of the most sophisticated methods to address uncer-
tainty allowed systematic propagation of uncertainty in all
model parameters and offered a statistical interpretation of
the joint distribution of incremental costs and effects. The
model outcomes (expected costs and QALYs of the strat-
egies) were based on the results of the probabilistic sensi-
tivity analysis (PSA) with 1,000 simulations. The results of
our study are in line and are comparable to the recently
published National Institute for Health Research (NIHR)
UK, document showing the value of hsTnT based early
diagnosis of AMI. This document also concludes that there
Vaidya et al. BMC Cardiovascular Disorders 2014, 14:77 Page 7 of 8
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alternative biomarkers alongside troponin [30].
Our estimation of post PPCI mortality is based on aver-
aged mortality figures reported by Rathore et al. and covers
the 15–240 min delay from diagnosis to PPCI after arrival
to hospital [3]. The study by Rathore et al. [3] shows that
more than 80% of patients underwent a PPCI within
120 minutes of hospital arrival, implying that the applied
average mortality rate in our model may be an overesti-
mation. Lower mortality rate will shift ICER more in favour
of hsTnT and would make hsTnT even more cost effective.
Our model conforms to the principles of good practice
for decision analytic models with use of transparent data
and modelling technique as per the guidelines laid by
the international society for pharmacoeconomics and
outcome research (ISPOR) task force [31]. Strength of
this model is its potential transferability as model inputs
can be adapted to a new setting easily. Inter- or intra-
country variations in costs, prevalence of AMI and
therapeutic intervention outcomes caused by availability
and accessibility of health care can be incorporated into
the model. Using cost effectiveness threshold from
WHO-CHOICE (world health organization – CHOosing
Interventions that are Cost Effective) project for ceiling
ratio in a particular country, cost effectiveness analysis
can be performed for that country [32].
The newly introduced hsTnT biomarker assay signifi-
cantly contributes to the early diagnosis of AMI and
appears to be a promising diagnostic intervention for
AMI. Although a multi-marker approach using hsTnT
and H-FABP may allow an early rule out of the disease
but economic modelling of cost and consequences for this
combination predicts its inferiority to hsTnT alone. More-
over, in a non ST elevation AMI patients study by Gian-
nitsis et al. showed that a doubling of the hs-TnT
concentration within 3 hours with the second concentra-
tion above the 99th percentile value is associated with a
positive predictive value for AMI of 100% and a negative
predicting value of 88% [33]. This indicates that with the
hsTnT assay within 3 hours instead of the 6 hours exam-
ined in this study, a definitive outcome can be obtained.
Conclusions
This economic evaluation concludes that hsTnT assay is a
cost effective alternative for the diagnosis of AMI to the
existing diagnostic marker assay in clinical practice. Com-
bination of two biomarkers, hsTnT and H-FABP for the
diagnosis of AMI does not bring any added advantage. Fu-
ture replacement of cTnT with hsTnT in clinical practice
is expected to save substantial health care costs and to im-
prove Health Related Qulaity of Life among AMI patients.
However, data for hsTnT and its combination with other
biomarkers from further research is needed to support
and strengthen the results of this modelling study.Abbreviations
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